Evidence map›Paper›PMID 37596534›Full record

ArticleBMC infectious diseases2023

Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020-2022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality.

Amr Kandeel, Yassmin Moatasim, Manal Fahim, Hala Bahaaeldin, Rabeh El-Shesheny, Wael H Roshdy, Mina N Kamel, Shaymaa Shawky, Mokhtar Gomaa, Amel Naguib and 14 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 1 country.

Amr KandeelPreventive Sector, Ministry of Health and Population, Cairo, Egypt.
Yassmin MoatasimCentre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt.
Manal FahimDepartment of Epidemiology and Surveillance, Preventive Sector, Ministry of Health and Population, Cairo, Egypt.
Hala BahaaeldinDepartment of Epidemiology and Surveillance, Preventive Sector, Ministry of Health and Population, Cairo, Egypt. halaaabahaa@gmail.com.
Rabeh El-SheshenyCentre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt.
Wael H RoshdyCentral Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt.
Mina N KamelCentre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt.
Shaymaa ShawkyCentral Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt.
Mokhtar GomaaCentre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt.
Amel NaguibCentral Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt.
Nancy El GuindyCentral Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt.
Ola DeghedyDepartment of Epidemiology and Surveillance, Preventive Sector, Ministry of Health and Population, Cairo, Egypt.
Reham KamelDepartment of Epidemiology and Surveillance, Preventive Sector, Ministry of Health and Population, Cairo, Egypt.
Mohamed KhalifaCentral Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt.
Ramy GalalPublic Health Initiatives, Cairo, 11613, Egypt.
Mohamed HassanyNational Hepatology and Tropical Medicine Research Institute, Ministry of Health and Population, Cairo, 11613, Egypt.
Galal MahmoudCentral Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt.
Ahmed KandeilCentre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt.
Salma AfifiMinistry of Health and Population Consultant, Cairo, Egypt.
Amira MohsenCommunity Medicine Department, National Research Centre, Cairo, Egypt.
Mohammad Abdel FattahPreventive Sector, Central Administration for Preventive Affairs, Ministry of Health and Population, Cairo, Egypt.
Ghazi KayaliHuman Link, Dubai, United Arab Emirates.
Mohamed A AliCentre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt.
Khaled AbdelghaffarMinister of Health and Population, Cairo, Egypt.
Ministry of Health and Population · EGNational Research Centre · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe o severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic has killed millions of people and caused widespread concern around the world. Multiple genetic variants of SARS-CoV-2 have been identified as the pandemic continues. Concerns have been raised about high transmissibility and lower vaccine efficacy against omicron. There is an urgent need to better describe how omicron will impact clinical presentation and vaccine efficacy. This study aims at comparing the epidemiologic, clinical, and genomic characteristics of the omicron variant prevalent during the fifth wave with those of other VOCs between May 2020 and April 2022.

methodsEpidemiological data were obtained from the National Electronic Diseases Surveillance System. Secondary data analysis was performed on all confirmed COVID-19 patients. Descriptive data analysis was performed for demographics and patient outcome and the incidence of COVID-19 was calculated as the proportion of SARS-CoV-2 confirmed patients out of the total population of Egypt. Incidence and characteristics of the omicron cohort from January- April 2022, were compared to those confirmed from May 2020-December 2021. We performed the whole-genome sequencing of SARS-CoV-2 on 1590 specimens using Illumina sequencing to describe the circulation of the virus lineages in Egypt.

resultsA total of 502,629 patients enrolled, including 60,665 (12.1%) reported in the fifth wave. The incidence rate of omicron was significantly lower than the mean of incidences in the previous subperiod (60.1 vs. 86.3/100,000 population, p < 0.001). Symptoms were reported less often in the omicron cohort than in patients with other variants, with omicron having a lower hospitalization rate and overall case fatality rate as well. The omicron cohort tended to stay fewer days at the hospital than did those with other variants. We analyzed sequences of 2433 (1590 in this study and 843 were obtained from GISAID platform) Egyptian SARS-CoV-2 full genomes. The first wave that occurred before the emergence of global variants of concern belonged to the B.1 clade. The second and third waves were associated with C.36. Waves 4 and 5 included B.1.617.2 and BA.1 clades, respectively.

conclusionsThe study indicated that Omicron-infected patients had milder symptoms and were less likely to be hospitalized; however, patients hospitalized with omicron had a more severe course and higher fatality rates than those hospitalized with other variants. Our findings demonstrate the importance of combining epidemiological data and genomic analysis to generate actionable information for public health decision-making.

Indexed as

COVID-19SARS-CoV-2EgyptEvolution, MolecularHumansPatient AcuityEpidemiologySARS-CoV-2 variantsSequencingWhole genome

Identifiers

PMID37596534
PMCPMC10439637
OpenAlexW4385971368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.